Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma

doi:10.3748/wjg.v18.i19.2364

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 19

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4326)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

409

HTML

3501

Figures (1-4)

211

Tables (1-3)

205

Sum=4326

May 21, 2012 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 21, 2012; 18(19): 2364-2370
Published online May 21, 2012. doi: 10.3748/wjg.v18.i19.2364

Table 3 Results of metallic stenting

	Patient group
	Radiotherapy	BSC	Pvalue
Cases	23	11
Mean stent patency (d)¹	604 ± 78.3	235 ± 53.3	0.0038
Median stent patency (d)¹	557	358
Stent obstruction (%)	12 (56.5)	4 (36.4)	0.4646
Mean patent period	329.2 ± 234.8	136.8 ± 147.1	0.1472
Cause
Tumor ingrowth	9	1	0.1133
Tumor overgrowth	1	1	0.5490
Sludge	2	2	0.5799

¹Mean and median stent patency were calculated using the Kaplan-Meier method and compared using the log rank test. Stent patency was significantly longer in the radiotherapy than in the BSC group. Mean patent period was longer in the radiotherapy than in the BSC group, but the difference was not significant. BSC: Best supportive care.

Citation: Isayama H, Tsujino T, Nakai Y, Sasaki T, Nakagawa K, Yamashita H, Aoki T, Koike K. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol 2012; 18(19): 2364-2370
URL: https://www.wjgnet.com/1007-9327/full/v18/i19/2364.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i19.2364